Ispronicline

Source: Wikipedia, the free encyclopedia.
Ispronicline
Clinical data
ATC code
  • none
Identifiers
  • (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine
JSmol)
  • C[C@@H](C/C=C/C1=CC(=CN=C1)OC(C)C)NC
  • InChI=1S/C14H22N2O/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15H,6H2,1-4H3/b7-5+/t12-/m0/s1 ☒N
  • Key:RPCVIAXDAUMJJP-PZBABLGHSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Ispronicline (TC-1734, AZD-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.[1]

It has also progressed to phase II as a potential treatment for ADHD. With dosages of 50 mg/day showing a significant improvement in ADHD symptoms[2][3]

Ispronicline is subtype-selective, binding primarily to the

neuroprotective effects.[medical citation needed
]

Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being dizziness and headache.[4][5][6][7][8] However, mid-stage clinical trials failed to show sufficient efficacy to continue development as a pharmaceutical drug.[1]

See also

References

  1. ^ a b Armental M (14 July 2014). "Targacept Drops Development of Alzheimer's Drug". Wall Street Journal.
  2. S2CID 44717647
    .
  3. ^ AstraZeneca (2009-10-29). "An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)". Targacept Inc.
  4. PMID 15179444
    .
  5. S2CID 22499622
    .
  6. S2CID 195688187
    .
  7. S2CID 10920515
    .
  8. S2CID 10056476
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ispronicline&oldid=1213227007"